XENCOR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.03 USD | +2.54% |
|
-2.17% | +8.48% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 76.05M | Sales 2025 * | 151M | Capitalization | 1.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -218M | Net income 2025 * | -165M | EV / Sales 2024 * | 18.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.19 x |
| P/E ratio 2024 * |
-6.32
x | P/E ratio 2025 * |
-8.46
x | Employees | 280 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xencor, Inc.
More recommendations
| 1 day | +1.56% | ||
| 1 week | +0.85% | ||
| Current month | +8.26% | ||
| 1 month | +18.88% | ||
| 3 months | -3.53% | ||
| 6 months | +17.95% | ||
| Current year | +6.78% |
1 week
20.31
22.93
1 month
17.9525.09
Current year
17.9526.84
1 year
16.4928.96
3 years
16.4943.61
5 years
16.4958.35
10 years
7.9358.35
| Managers | Title | Age | Since |
|---|---|---|---|
Bassil Dahiyat
FOU | Founder | 53 | 97-07-31 |
John Desjarlais
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-06-30 |
Charles Liles
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 66 | 17-04-13 |
Richard Ranieri
BRD | Director/Board Member | 71 | 17-12-18 |
Alan Montgomery
BRD | Director/Board Member | 70 | 15-03-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 25 M€ | -1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 23.03 | +2.54% | 658 302 |
| 24-05-16 | 22.46 | +5.50% | 1,294,915 |
| 24-05-15 | 21.29 | +4.57% | 575,146 |
| 24-05-14 | 20.36 | -4.59% | 563,923 |
| 24-05-13 | 21.34 | -5.07% | 541,815 |
Delayed Quote Nasdaq, May 17, 2024 at 10:03 am EDT
More quotes
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Calendar
2024-06-13
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
22.46
USD
Average target price
35.92
USD
Spread / Average Target
+59.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.78% | 1.38B | |
| +8.57% | 114B | |
| +10.55% | 104B | |
| -12.71% | 22.41B | |
| -0.32% | 22.28B | |
| -5.75% | 19.07B | |
| -37.36% | 18B | |
| -5.68% | 17.89B | |
| +6.98% | 14.28B | |
| +36.59% | 12.55B |
- Stock Market
- Equities
- XNCR Stock
